BCMA CAR T-Cell Therapy Yields High Remission Rate in Multiple Myeloma
June 6th 2017Early results from a Chinese study showed that 33 of 35 patients (94%) with relapsed or refractory multiple myeloma experienced clinical remission after treatment with chimeric antigen receptor T cells targeting B-cell maturation protein.